ssio 2019

You can download the agenda from here:

08.30 – 09.00 Registration

T CELL RECEPTOR SPECIFICITIES
Chairs: F. Cavallo (IT), G. Kvalheim (NO)

09.00–09.40 Unrelated stem cell donors for the treatment of haematological malignancies A. Madrigal (UK)

                 

09.40 – 13.10 IMMUNOTHERAPIES I
Chairs: F. Cavallo (IT), G. Kvalheim (NO)

09.40–10.20 Translating old discoveries into tomorrow’s cancer immunotherapy E. M. Inderberg (NO)

10.20–11.00 T-cell therapy- bringing discovery into the clinic G. Kvalheim (NO)

11.00-11.10 Coffee Break

11.10-11.50 TCR structure and function – Clinical trials M. Nishimura (USA)

11.50-12.30 Tumor ablation and immune stimulation G. Adema (NL)

 12.30-13.10 Targeting xCT in metastatic breast cancer treatment. F. Cavallo (IT)

13.10-14.30 Light lunch


14.30-16.30 IMMUNOTHERAPIES ΙΙ
Chairs: A. Kotsakis(GR), A. Koumarianou (GR) 

14.30-15.10 NSCLC: updated data with ICIs I. Mountzios (GR)

15.10-15.50 Immunotherapy for the treatment of urothelial cancer N. Pistalmatzian (GR)

15.50-16.30 Biomarkers and immune resistance C.N. Baxevanis (GR)

 

16.30-18.30 Getting together

The students meet the experts in small parallel groups and discuss aspects from their presentations6.3

09.00-16.30 IMMUNE SUPPRESSION-RESISTANCE-IMMUNE CHECKPOINTS
Chairs: S. Ostrand-Rosenberg (USA), B. Seliger (DE)

9.00–9.40 T-cell suppression by cancer cells; off the beaten track P.T. Straten (DK)

9.40–10.20 The role of myeloid-derived suppressor cells in tumor immune evasion V. Bronte (IT)

10.20-11.00 Coffee Break

11.00-13.00 IMMUNE SUPPRESSION-RESISTANCE-IMMUNE CHECKPOINTS ΙΙ 
Chairs: C.N. Baxevanis (GR), G. Adema (NL)

11.00-11.40 Modulation of immune responses via PD-L1 targeting S. Ostrand-Rosenberg (USA)

11.40-12.20 Immune escape and resistances to immune check point inhibitors B. Seliger (DE)

 12.20-13.00 Ageing and the human immune system in the era of cancer immunotherapy:  is it
all downhill? G. Pawelec (DE)

13.00-14.30 Light lunch

14.30-16.30 IMMUNE SUPPRESSION-RESISTANCE-IMMUNE CHECKPOINTS ΙΙΙ
Chairs: P. Foukas (GR), A. Kotsakis (GR)

14.30.-15.10 The Melanoma paradigm for anti-cancer immunotherapy Α. Laskarakis (GR)

15.10-15.50 Immune biomarkers A. Giatromanolaki (GR)

15.50-16.30 Mechanisms of immune resistance Ch. Kosmas (GR)

Getting together

16.30-18.30 The students meet the experts in small parallel groups and discuss aspects from their presentations

10.00-13.00 T CELL RECEPTOR SPECIFICITIES
Chairs: V. Georgoulias (GR), C.N. Baxevanis (GR)

10.00–10.40 The (tremendous) gap between the epitopes predicted, and those actually recognized by CD8 T cells G. Kirchenbaum (USA)

 10.40-11.20 T-cell monitoring for clinical studies: main techniques, pitfalls and quality assurance  C. Gouttefangeas (DE)

11.20-11.40 Coffee Break

11.40-13.00 T CELL RECEPTOR SPECIFICITIES ΙΙ
Chairs: G. Pawelec (DE), N. Diamantopoulos (GR) 

11.40-12.20 Immune check point inhibitors for the treatment of the head and neck cancer N. Diamantopoulos (GR)

12.20-13.00 Management of immune related toxicity A. Koumarianou (GR)

 13.00-14.15 Light Lunch

Getting together

14.15-16.15 The students meet the experts in small parallel groups and discuss aspects from their presentations22